Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
- DOI
- 10.1016/s0140-6736(25)02105-1
- Published
- 2026 Feb 28
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-25-02105-1,
title = {Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.},
author = {Nauck MA and Tuttle KR and Tschöp MH and Blüher M},
year = {2026},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(25)02105-1},
url = {https://doi.org/10.1016/s0140-6736(25)02105-1}
}RIS
TY - JOUR TI - Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. AU - Nauck MA AU - Tuttle KR AU - Tschöp MH AU - Blüher M PY - 2026 JO - Lancet (London, England) DO - 10.1016/s0140-6736(25)02105-1 UR - https://doi.org/10.1016/s0140-6736(25)02105-1 ER -
APA
MA, N., KR, T., MH, T., & M, B. (2026). Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)02105-1
Source records
- pubmed · retrieved 2026-09-26T16:26:10.873Z